Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 2nd Preview)
-
Big pharma strikes major RNA deal for autoimmune T-cell engager
Novartis moved to lock in an early RNA immunotherapy pipeline by licensing Abogen Biosciences’ in vivo autoimmune T-cell engager ABO2203 in a deal worth up to $7.8 billion, including $575 million upfront. The asset is an mRNA-encoded CD19xCD3 T-cell engager intended to reset B cells through depletion. The agreement grants Novartis exclusive worldwide rights to ABO2203 and includes options to license additional assets built on Abogen’s proprietary RNA platform. Closing is subject to customary regulatory clearances, with milestone payments tied to development, regulatory and commercial progress. Abogen described the deal as a validation that its RNA platform can expand beyond prophylactic vaccines into therapeutics, while Novartis framed the approach as a complement to existing autoimmune modalities via in vivo production.
-
Phase 2 readout lifts Pfizer into stronger eczema competition
Pfizer reported mid-stage efficacy for tilrekimig (a trispecific antibody targeting IL-4, IL-13 and TSLP) in a Phase 2 trial in moderate-to-severe atopic dermatitis. In the latest disclosed 16-week data, significantly more patients treated with tilrekimig achieved stronger skin clearance than placebo. The company said the highest-dose arms reached a 75% reduction in disease scope and severity versus placebo, and it framed the results as supporting advancement into more advanced testing. Pfizer also referenced plans to evaluate tilrekimig in asthma, chronic obstructive pulmonary disease and further atopic dermatitis development, including head-to-head work against Dupixent. With Dupixent facing a patent cliff starting in 2031, the readout adds another candidate to the crowded IL-4/IL-13 and downstream inflammatory-pathway race.
-
CRISPR therapy secures FDA BLA approval for hereditary angioedema
The FDA approved Intellia Therapeutics’ one-time in vivo CRISPR medicine lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, clearing a key regulatory step after successful Phase 3 results. Lonvo-z uses an mRNA-lipid nanoparticle delivery system designed to treat the unpredictable, potentially life-threatening swelling attacks of HAE. The BLA approval follows reported Phase 3 HAELO trial outcomes published in the New England Journal of Medicine. In interviews cited with the approval coverage, investigators emphasized that while existing therapies can prevent attacks, unpredictability and quality-of-life burdens remain major unmet needs. This approval strengthens the case for mRNA-LNP delivered genome editing as a practical therapeutic option beyond the exploratory stage, and it adds momentum for wider adoption of gene-editing modalities in rare diseases.
-
New Biotech funding: AnaCardio pushes oral HFrEF drug to Phase IIb
AnaCardio secured a €62.5 million ($70.5 million) Series B to advance AC01, its oral calcium-sensitizing contractile agent for chronic advanced heart failure with reduced ejection fraction. The company said it will fully fund Phase IIb development and target Phase III readiness by 2028. AC01, a ghrelin mimetic small molecule, was originally in-licensed from Helsinn in 2022 and is designed to improve cardiac contractility through a differentiated pathway. AnaCardio cited encouraging Phase Ib/IIa results published in The Lancet to support the move to a larger patient population. Regulatory engagement was also highlighted, with positive scientific advice referenced from both the FDA and EMA, while co-leads Novo Holdings and the Ljungström family office brought in additional investors including Helsinn and Innovestor Life Science.
-
Immuno-oncology fails to deliver expected T-cell boost in melanoma
A clinical trial combining an IDO1 inhibitor with a therapeutic melanoma vaccine did not boost tumor-fighting T cells as intended, according to the disclosed trial results led by Craig L. Slingluff of the University of Virginia. Investigators tested whether blocking IDO1, an immunosuppressive enzyme in tumors, would amplify vaccine-driven immune responses. The outcome, described as scientifically valuable despite lack of the anticipated immunologic effect, points to limits in translating IDO1 blockade into measurable gains for the selected endpoints. The work underscores the importance of identifying which tumor immune contexts actually respond to IDO1 targeting. For drug developers, the negative immunology signal may inform biomarker selection and combination strategy refinement in future melanoma vaccine programs and broader checkpoint-adjacent vaccine efforts.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.